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Aims The purpose of this study was to identify novel genetic variants influencing circulating asymmetric dimethylarginine
(ADMA) and symmetric dimethylarginine (SDMA) levels and to evaluate whether they have a prognostic value on car-
diovascular mortality.
Methods
and results
Weconducted a genome-wide association study on themethylarginine traits and investigated the predictive value of the
new discovered variants on mortality. Our meta-analyses replicated the previously known locus for ADMA levels in
DDAH1 (rs997251; P ¼ 1.4 × 10240), identified two non-synomyous polymorphisms for SDMA levels in AGXT2
(rs37369; P ¼ 1.4 × 10240 and rs16899974; P ¼ 1.5 × 10238) and one in SLC25A45 (rs34400381; P ¼ 2.5 × 10210).
We also fine-mapped the AGXT2 locus for further independent association signals. The two non-synonymous AGXT2
variants independently associated with SDMA levels were also significantly related with short-term heart rate variability
(HRV) indices in young adults. Themajor allele (C) of the novel non-synonymous rs16899974 (V498L) variant associated
with decreased SDMA levels and an increase in the ratio between the low- and high-frequency spectral components of
HRV (P ¼ 0.00047). Furthermore, the SDMA decreasing allele (G) of the non-synomyous SLC25A45 (R285C) variant
was associated with a lower resting mean heart rate during the HRV measurements (P ¼ 0.0046), but not with the
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HRV indices. None of the studied genome-wide significant variants had any major effect on cardiovascular or total mor-
tality in patients referred for coronary angiography.
Conclusions AGXT2has an important role in SDMAmetabolism in humans.AGXT2mayadditionally have anunanticipated role in the
autonomic nervous system regulation of cardiac function.
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Introduction
Increasing evidence shows that both asymmetric dimethylarginine
(ADMA) and symmetric dimethylarginine (SDMA) might have inde-
pendent roles in cardiovascular diseases1 and the prediction of car-
diovascular events.2,3 Elevated circulating SDMA levels have been
reported to be associated with increased mortality in stroke
patients,4 an increased risk of cardiac death in patients with non-
ST-segment elevation myocardial infarction,5 and worse prognosis
in patients referred for coronary angiography.3 Indeed, increasing in
vitro and in vivo evidence support the concept that SDMA may have
an independent role in the pathogenesis of cardiovascular diseases.
Symmetric dimethylarginine induces reactive oxygen species pro-
duction of monocytes6 and promotes inflammation in chronic
kidney disease.7 Moreover, recent data show that SDMA may
promote endothelial dysfunction.8
Previouscandidate gene studieshave identifieda limitednumberof
single-nucleotide polymorphisms (SNPs) associated with plasma
ADMA levels in the dimethylarginine dimethylaminohydrolase-1
and -2 (DDAH1 andDDAH2) loci,9 whereas the genetic variants regu-
lating SDMA levels are not known. There is evidence that AGXT2
plays a role in both ADMA and SDMA metabolisms in vivo,10 but as-
sociation data between genetic variants and circulating methylargi-
nine levels in humans are currently lacking. Furthermore, AGXT2
knockout mice show a hypertensive phenotype, but the underlying
mechanisms behind this observation are not currently well under-
stood.11 To investigate the role of AGXT2 in health and disease in
humans, the identification of the functional genetic variants affecting
the enzymatic activity of the AGXT2 protein and the regulation of its
expression in different human tissues is of major importance.
Therefore, to identify additional new loci forADMA, andespecially
for SDMA,weperformed the firstmeta-analyses of genome-wide as-
sociation (GWA) studies for the methylarginines using data from
5110participants fromtheYoung Finns Study (YFS) and the Ludwigs-
hafen Risk and Cardiovascular Health (LURIC) study. Secondly, we
fine-mapped the AGXT2 locus, that showed the strongest association
with SDMA, for variants independently affecting circulating SDMA
levels. Finally,we tested the associationof these variantswithmortal-
ity endpoints in LURIC and heart rate variability (HRV) parameters in
YFS to be able to characterize the pathophysiological role of these
new AGXT2 variants.
Methods
The study flow is summarized in Figure 1.
Study populations
We conducted a meta-analysis of GWA data on 5110 individuals of
European descent drawn from two large cohorts: the YFS and the
LURIC study. The YFS cohort is a Finnish longitudinal population study
sample on the evolution of cardiovascular risk factors from childhood
to adulthood.12 In the present study, we used the variables measured
in 2001. The LURIC study consists of 3316 Caucasian patients hospita-
lized for coronary angiography between 1997 and 2000 at a tertiary
care centre in Southwestern Germany.13 Clinical indications for angiog-
raphy were chest pain or a positive non-invasive stress test suggestive of
myocardial ischaemia. To limit clinical heterogeneity, individuals suffering
from acute illnesses other than acute coronary syndrome, chronic non-
cardiac diseases, and a history of malignancy within the 5 past years
wereexcluded. See further description andcharacteristics in Supplemen-
tary material online, Methods S1 and Table S1.
Biochemical
Asymmetric dimethylarginine and symmetric dimethylarginine were
measured from frozen serum using the same reversed-phase high-
performance liquid chromatography method in both studies. For
Figure 1 Study population and flow. Flow diagram depicting the
cohorts and numbers of participants. The associations of the
AGXT2 variants identified in the conditional analysis with heart
rate variability and sudden cardiac death were investigated in the
Young Finns Study and Ludwigshafen Risk and Cardiovascular
Health cohorts, respectively.
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details and other biochemical measurements, see Supplementary mater-
ial online, Methods S2.
Genotyping and quality control
In LURIC, genotyping was done by using the Affymetrix Human SNP
Array 6.0 at the LURIC Study facility. In the YFS, genotyping was done
using a custom-built Illumina Human 670k BeadChip at the Welcome
Trust Sanger Institute (Supplementary material online, Methods S3).
Genotype imputation was performed using minimac14 and IMPUTE215
in LURIC and YFS, respectively. Genotype imputation in both studies
was performed using 1000 Genomes Phase I Integrated Release
Version 3 (March 2012) samples as a reference. We excluded imputed
SNPs and insertion–deletion polymorphisms with low imputation
quality (minimac Rsq ,0.3 or IMPUTE info ,0.4) and allele frequency
of ,0.1%. After the exclusions, 10 085 758 imputed genetic variants
were available in both studies.
Short-term heart rate variability
We used the ratio between low- and high-frequency components (LF/
HF) of spectral HRV to estimate sympathovagal balance in the YFS parti-
cipants. The mean heart rate during HRV measurement was used as an
estimate of the resting heart rate. Breathing was metronome controlled
at the frequency of 0.25 Hz. We excluded subjects with current anti-
hypertensivemedications, Type1diabetes, pregnantwomen, andbreast-
feeding women. After these exclusions, genotype datawere available for
1723 subjects and were included in the association analyses. For details,
see Supplementary material online, Methods S4.
Classification of SCD cases
In LURIC, sudden cardiac death (SCD) was defined as sudden unexpect-
eddeatheitherwithin 1 hof symptomonsetorwithin 24 hof havingbeen
observed alive and symptom-free. Patients who suffered from any non-
cardiac chronic and terminal disease (e.g. cancer), so that their death
was not unexpected, and those whose sudden death was most likely
attributed to a non-cardiac cause were not classified as SCD cases. See
Supplementary material online, Methods S4 for more details about the
cause of death classifications.
Statistical analysis
To identify and correct for population stratification, we performed an
MDS analysis as implemented in PLINK 1.07.16 In both studies, residual
ADMA and SDMA concentrations or residuals of ADMA/SDMA ratio
were determined after regression adjustment using the R software. Out-
liers (≥4 SD from the mean) were removed from the dimethylarginine
phenotype values before covariate adjustment to avoid spurious associa-
tions (typically 5–20 data points for any one outcome). Residuals were
obtained using linear regression analysis in which the dimethylarginine
phenotypes were adjusted for sex, age, body mass index, and serum cre-
atinine to account for variation in renal function, as well as the first three
MDS components to control for population stratification. As circulating
ADMA is amajor determinant of SDMA levels and vice versa,3 themodel
for ADMA was additionally adjusted for SDMA and that for SDMA was
adjusted for ADMA. Residuals were normalized to have a mean of 0
andSDof 1using inverse-normal transformation.Theassociationanalysis
of the imputed SNPs and indels assuming an additive genetic model was
carried out utilizing the SNPTEST v2.4.117 and ProbABEL v. 0.3.018 soft-
wares in YFS and LURIC, respectively. Quantile-quantile and Manhattan
plots were drawn for the analysis of the results. To estimate howwell the
distributionwas calibrated, for each phenotype in both studies, we calcu-
lated the genomic inflation factor (l) from all imputed variants. The l for
each trait in both studies ranged from 0.993 to 1.012, suggesting that
there was no major residual confounding by population stratification,
and little evidence of cryptic relatedness. We created the regional asso-
ciation plots using LocusZoom.19 The summary results from both
cohorts were meta-analyzed with the random-effects meta-analysis
method implemented in GWAMA.20 A stringent genome-wide signifi-
cance level of 1.66 × 1028 was set to correct for multiple testing of
the three phenotypes.
We fine-mapped the AGXT2 locus using a series of sequential condi-
tional analyses by adding the most strongly associated SNP into the re-
gression model as a covariate and using the inverse-normal
transformed residuals as anoutcomevariable to test all remaining region-
al SNPs for association. The results from both studies were combined
using a random-effects meta-analysis. We repeated this procedure until
the strongest SNP showed a conditional P-value of .1024.
Further statistical analyses were performed using R 3.0.0 (http://www.
r-project.org). A Cox regression proportional hazards analysis was per-
formed to test whether the AGXT2 and SLC25A45 genotypes were asso-
ciated with mortality endpoints. The risk of mortality was quantified as
hazard ratios (HRs). The proportional hazards assumption was checked
with Schoenfeld’s residuals and was met for all models. The screening
tests were conducted using age and sex as covariates and an additive
genetic model. Further analyses were performed adjusting for well-
established SCD risk factors. Secondly, to investigate the possible mech-
anism underlying the associations with SCD, analyses were stratified
according to the median value of left ventricular systolic pressure
(LVSP). Finally, the associations with HRV variables were tested using
linear regression analysis. Genotyped data were used for rs37369 in
LURIC. For all other SNPs and analyses, imputed data were used. Imput-
ation quality parameters and minor allele frequencies for AGXT2 and
SLC25A45 SNPs are provided in Supplementary material online, Table S2.
Results
Genome-wide association studies for
dimethylarginines and their ratio
WecarriedoutGWAmeta-analysesonADMA,SDMA,and their ratio
using data from the YFS and LURIC populations, involving a total of
5110 individuals of European ancestry. The strongest associations
for each locus from the meta-analyses are summarized in Table 1,
with an index SNP representing the most significant association la-
belled for each independent signal. Across the genome, the most sig-
nificant association for ADMA levels (P ¼ 1.4 × 10240) was on
chromosome 1p22 harbouring DDAH1, which encodes the key regu-
latory enzyme of ADMA metabolism DDAH. The most significant
signal for SDMA levels (P ¼ 1.4 × 10240) was on chromosome
5p13 at rs37369 (V140I) in the coding sequence of alanine–glyoxylate
aminotransferase 2 (AGXT2). Another genome-wide significant signal
for SDMA levels (P ¼ 2.5 × 10210) was identified in the coding se-
quence of a mitochondrial carrier protein SLC25A45 at rs34400381
(R285C).A list of suggestive signals foreach trait not reaching genome-
wide significance is provided in Supplementary material online, Tables
S4 and S5.
Fine-mapping of the AGXT2 region
Next, we fine-mapped the newly identified AGXT2 region showing
the strongest association with SDMA for additional independent
signals using sequential conditional analysis. Of the methylarginine
traits, SDMA was used as an outcome variable in this analysis,
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because it showed the strongest association with AGXT2 variants in
the original meta-analysis. Interestingly, another independent
genome-wide significant association was pinpointed at rs16899974
(V498L) when conditioning on the top SNP at rs37369 (V140I)
(Figure 2A and B). In the next step, when adjusting for the two mis-
sense mutations (rs37369 and rs16899974), a number of intronic
variants showed significant association (P, 1024) with SDMA
after correcting for multiple testing in the AGXT2 region
(Figure 2C). No other informative (P, 1024) intronic or coding
sequence AGXT2 variants were identified when further adjusting
for the top intronic variant rs13165070 (Figure 2D).
Association of non-synonymous AGXT2
variants with heart rate variability in young
adults (Young Finns Study)
The SDMA decreasing alleles of the studied AGXT2-coding variants
wereassociatedwith an increase in the ratiobetweenLFandHFspec-
tral components of the short-termHRV in the YFS (Table 2). The as-
sociationwas especiallymarkedbetween thenovel non-synonymous
rs16899974 (V498L) variant and the LF/HF ratio (P ¼ 0.00047).
None of the variants showed an association with the LF component
(always P . 0.20). Instead, rs16899974 (V498L) variant showed a sig-
nificant association (P ¼ 0.028) with the HF component (estimate of
vagal tone). The non-synonymous SLC25A45 rs34400381 (R285C)
variant was not associated with the LF/HF component (P ¼ 0.39),
but the SDMA decreasing allele (G) was associated with a decrease
in the resting mean heart rate during the HRV measurements inde-
pendent of the LF/HF ratio (Table 2). Further adjustment for serum
ADMA or SDMA levels did not change our results.
Associations between non-synonymous
AGXT2 and SLC25A45 variants with
mortality in Ludwigshafen Risk and
Cardiovascular Health
Finally, we investigated whether the non-synonymous AGXT2- and
SLC25A45-coding variants independently associated with AGXT2
substrate levels could also predict mortality among patients referred
for coronary angiography. None of the studied non-synonymous
AGXT2 or SLC25A45 SNPs were associated with all-cause or cardio-
vascular mortality (always P. 0.05). However, the SDMA decreas-
ing major allele (G) of the SLC25A45 polymorphism (rs34400381,
R285C) was associated with an increased risk for SCD with per
allele HR of 13.0 (95% CI 1.54–110, P ¼ 0.018). The two non-
synonymous AGXT2 variants were not associated with SCD in the
whole study population.However, both variants showed a significant
interactionwith LVSPon SCD (Table 3).AGXT2 rs16899974 (V498L)
showed a nominally significant associated with SCD in the low LVSP
group (P ¼ 0.021), whereas therewas a trend towards an association
for rs37369 (P ¼ 0.10). Analogously to the association for the
SLC25A45 variant (R285C), the SDMA decreasing alleles were asso-
ciatedwith an increased risk for SCD.Noassociationswereobserved
between theAGXT2 variants and SCD in the high LVSP group (all P .
0.20), and there was no significant interaction between SLC25A45
rs34400381 and the LVSP status on SCD (P ¼ 0.63). Additional
adjustments for circulating ADMA or SDMA did not materially
change our results.
Discussion
We report the first GWAS results on circulating ADMA and SDMA
levels based on meta-analyses of 5110 individuals of European
ancestry, and provide strong evidence that two common non-
synonymous-coding variants in AGXT2 and one non-synonymous-
coding variant in SLC25A45 (R285C) are independently associated
with circulating SDMA levels. Moreover, we document that the non-
synonymous AGXT2 and SLC25A45 variants showed associations
with the LF/HF component of spectral HRV and resting heart rate
in young adults, respectively.
The polymorphism (rs37369) with the strongest association with
circulating SDMA codes for a non-synonymous valine-to-isoleucine
(V140I) substitution in the AGXT2 protein. Another non-synomyous
AGXT2 rs16899974 (V498L) SNP and a number of intronic variants
were also associated independently with SDMA levels. The lead in-
tronic variant (rs13165070) identified in the conditional analysis is in
a high linkage disequilibrium (r2¼ 0.9) with intronic rs10521021 that
has been previously associated with AGXT2 mRNA levels in the
human liver.21TheTalleleof rs37369 is associatedwithboth increased
circulating SDMA levels in the present study and increased levels of
urinary 3-aminoisobutyrate (BAIB) metabolite.22 These results to-
gether refer to the possibility that the two novel non-synomyous
AGXT2variantsmaycontributetoplasmaSDMAlevelsthroughtheen-
zymatic decomposition of SDMA in the kidneys. Indeed, AGXT2
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Table 1 Genome-wide significant associations for each methylarginine trait in the meta-analyses
Trait Variant Locus Chr. Position EA NEA EAF (%) n b (SE) P-value
ADMA rs28489187 Intron of DDAH1 1 85 797 110 G A 21.6 5105 0.37 (0.028) 1.39 × 10240
SDMA rs37369 CDS of AGXT2 (V140I) 5 35 037 115 T C 8.8 5103 0.47 (0.035) 1.42 × 10240
SDMA rs1884139 Intron of DDAH1 1 85 845 998 T G 37.1 5103 20.18 (0.020) 9.65 × 10219
SDMA rs34400381 CDS of SLC25A45 (R285C) 11 65 143 892 A G 4.3 5102 0.36 (0.056) 2.48 × 10210
ADMA/SDMA rs37369 CDS of AGXT2 (V140I) 5 35 037 115 T C 8.8 5102 20.41 (0.035) 2.08 × 10232
ADMA/SDMA chr1:85897175:D Intron of DDAH1 1 85 897 175 A ATCC 17.4 5102 0.27 (0.027) 3.85 × 10224
Chr., chromosome; position, variant position inNCBI human build 37; EA andNEA, effect allele and non-effect allele; EAF, effect allele frequency; CDS, coding sequence;b, effect size
in standard deviations per copy of the effect allele, ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine.
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expression in the kidney has recently been shown to be inversely cor-
related with both circulating ADMA and SDMA levels in humans.11
SDMA is transaminated to a-keto-d-(N,N′-dimethylguanidino)valeric
acid (DMGV′) by AGXT2.23 Our findings support the hypothesis
that this mitochondrial24 AGXT2-related pathway can effectively
metabolize SDMA in humans. Moreover, measurable quantities of
Figure2 Regional plots for fine-mapping results in the AGXT2 region. Fine-mapping of theAGXT2 region for independent association signals using
sequential conditional analysis and circulating symmetric dimethylarginine levels as an outcome variable. Original meta-analysis (A), adjusted for
rs37369 (V140I) (B), additionally adjusted for rs16899974 (V498L) (C ), and additionally adjusted for rs13165070 (D). Signals above the red line
(P, 1 × 1024) were considered to exhibit evidence of association in the AGXT2 region.
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Table 2 Associations between non-synonomyousAGXT2 and SLC25A45 variants with symmetric dimethylarginine, heart
rate variability, and resting heart rate
SNP Gene Effect allele EAF (%) GWAS meta-analysis
(n 5 5110)
Young Finns (n5 1723)
SDMA lnLF/HF Mean HR (b.p.m.)
b (SE) P-value b (SE) P-value b (SE) P-value
rs37369 (V140I) AGXT2 C 91.2 20.47 (0.035) 1.4 × 10240 0.10 (0.052) 0.045 20.54 (0.58) 0.36
rs16899974 (V498L) AGXT2 C 77.2 20.32 (0.024) 1.5 × 10238 0.13 (0.036) 0.00047 20.73 (0.41) 0.073
rs34400381 (R285C) SLC25A45 G 95.7 20.36 (0.056) 2.5 × 10210 0.055 (0.064) 0.39 22.02 (0.71) 0.0046
Per effect alleleb (SE) fromconditional linear regressions. Effect alleles are SDMAdecreasing alleles from theGWASmeta-analysis. Models for the ln-transformed LF/HF component
of short-term HRV are adjusted for age, sex, and heart rate. Models for the mean heart rate are adjusted for age, sex, and lnLF/HF.
EAF, effect allele frequency; HR, heart rate; b.p.m., beats per minute; SE, standard error; SNP, single-nucleotide polymorphisms; SDMA, symmetric dimethylarginine; LF/HF, the ratio
between the low- and high-frequency spectral components of heart rate variability.
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a-keto-d-(N,N-dimethylguanidino)valeric acid (DMGV), the trans-
amination product of ADMA by AGXT2, was recently reported
being present in human plasma and urine.25
We observed a genome-wide significant association for SDMA at
rs34400381 (R285C) in SLC25A45 encoding a mitochondrial inner-
membrane transporter protein. Interestingly, SLC25A45 has the
same intracellular localization than AGXT2, although its function is
notwell known.26 The association is a highly genome-wide significant
in the YFS (P ¼ 2.4 × 1029), but only nominally significant in LURIC
(P ¼ 0.026). This association clearly needs replication in an inde-
pendent population.
Our data suggests that non-synonymous AGXT2 variantsmay have
an effect on the autonomic balance mainly by modulating the vagal
tone, because AGXT2 rs16899974 was associated with both the LF/
HFratio and thevagal componentHFofHRValone.Thephysiological
interpretation of LF/HF is not straightforward. The LF component
wasobserved tobe correlatedwith baroreflex function.27Moreover,
both HF and LF have been shown to be reduced by atropine admin-
istration, indicating that both spectral components of HRV are under
vagal control,28 in linewith the idea that under resting conditions var-
iations in the heart rate are largely dependent on vagal modulation.29
Nevertheless, increased LF/HF and decreased HF have been previ-
ously associated with increased prevalence of the metabolic syn-
drome in the YFS cohort.30 Moreover, decreased HRV appears to
be associated with hypertension, dyslipidaemia, impaired glucose
metabolism, increased ventricular arrhythmias, and mortality.31–35
In the present study, we also showed that a non-synonymous
SLC25A45 variant (R285C) was associated with a decreased resting
heart rate during the HRV measurements, but not with HRV
indices. Theobservation that the adjustment for circulatingmethylar-
ginine levels did not change the results suggests that the associations
between the AGXT2- and SLC25A45-coding variants and heart rate
regulation could be mediated through transamination of other
AGXT2 substrates than methylarginines. Although further studies
are needed to understand the molecular mechanisms underlying
the associations between heart rate regulation and non-synonymous
variants within AGXT2 and SLC25A45, it is tempting to speculate that
transamination activity of AGXT2 on g-aminobutyric acid isomers
glycine and/orb-aminoisobutyric acid (BAIB), a partial glycine recep-
tor agonist36 couldplaya role explaining the associations. The striking
association of AGXT2 rs37369 with urinary BAIB levels22 and the
presence of glycinergic synaptic inputs to cardiac vagal neurons in
the brainstem nuclei37 support this hypothesis.
None of the genome-wide significant variants were associated
with cardiovascular or overall mortality. Interestingly, the AGXT2
substrate (SDMA) decreasing major allele (G) of the non-
synonymous SLC25A45 (R285C) variant was associated with an
increased risk for SCD in the whole LURIC population independent
of circulationmethylarginine levels.However, this association should
be interpreted with conscious due to the moderate imputation
quality for the variant (Rsq¼ 0.43). Moreover, we observed signifi-
cant interactions between the pressure creation capacity of the left
ventricle and the two non-synonymous AGXT2 variants on SCD.
We used LVSP to quantify the degree of the systolic dysfunction
and heart failure. Both the increased sympathic drive38 and the para-
sympathic withdrawal39 are integral components of congestive heart
failure. It has been known for decades that sympathetic activation can
trigger fatal ventricular arrhythmias, whereas vagal activity may exert
a protective effect.38 Interestingly, the HF HRV decreasing major
allele (C) of rs16899974 was associated with an increased risk for
SCD in patients with impaired systolic function, but not in those
with preserved LVSP. Although theAGXT2 substrate levels decreas-
ing alleles of these variants are consistently associated with an
increased risk for SCD, these results should be considered as ex-
planatory and a replication in an independent population is
warranted.
Based on our results, it may be worth investigating whether
AGXT22/2 animals have altered vagal tone compared with wild-
type animals, and whether they are protected against ventricular
arrhythmia in an experimental model of myocardial infarction
(MI)-induced systolic heart failure. The associations with the HRV
parameters and SCD should also be investigated in an independent
population of MI and heart failure patients.
The present study has several strengths and limitations that warrant
consideration.The strengths include large,well-characterizedcohorts,
the prospective design, and long-term follow-up with prospectively
adjudicated SCDcases. Thepotential limitations include thepossibility
of somedegreeofmisclassificationofSCDcases.However, this kindof
bias is likely to lead to an underestimation rather than an overesti-
mation of the true genetic effects. Moreover, the generalizability of
the SCD association with the general population and other ethnic
groups may be limited. Finally, although we attempted to adjust for
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Associations between non-synonomyous AGXT2 variants and sudden cardiac death
SNP Gene Effect allele EAF (%) All (n5 2748,
173 SCDs)
LVSP < 145 mmHg
(n 5 1220, 66 SCDs)
LVSP ≥ 145 mmHg
(n 5 1199, 83 SCDs)
P for
interaction
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
rs37369 AGXT2 C 91.2 1.04 (0.70–1.55) 0.83 1.98 (0.88–4.45) 0.10 0.72 (0.44–1.19) 0.20 0.041
rs16899974 AGXT2 C 77.2 1.17 (0.87–1.55) 0.30 1.84 (1.10–3.09) 0.021 0.81 (0.55–1.21) 0.31 0.035
Pereffect alleleHRs (95%CI) fromconditionalCox regressions. Effect alleles are SDMAdecreasing alleles from theGWASmeta-analysis. Allmodels are adjusted for age, sex,Cystatin
C, HbA1c, beta blocker use, left ventricular hypertrophy (ECG), and cardiomyopathy.
SCD, sudden cardiac death; EAF, effect allele frequency; HR, hazard ratio per effect allele increase; CI, confidence interval; LVSP, left ventricular systolic pressure in coronary
angiography; SNP, single-nucleotide polymorphism.
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all relevant covariates, we could not rule out the possibility of residual
confounding.
In summary, our data clearly indicate that two coding sequences
SNPs rs37369 (V140I) and rs16899974 (V498L) in AGXT2 are asso-
ciated with circulating SDMA levels in two large cohorts of healthy
adults and patients referred to coronary angiography, supporting
the idea that AGXT2 has a physiological role in the SDMAmetabol-
ism in humans. The two non-synomyous AGXT2 variants showed
associations with the LF/HF component of spectral HRV, whereas
the novel non-synomyous SLC25A45 variant was associated with
the resting heart rate in young adults. AGXT2 and SLC25A45 may
have unanticipated roles in the regulation of autonomic balance
and heart rate in health and disease.
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